Indication
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Vizimpro 15 MG Comprimidos Recubiertos con PeliculaSpain · 15.576 mgMarketed
- Vizimpro 30 MG Comprimidos Recubiertos con PeliculaSpain · 31.153 mgMarketed
- Vizimpro 45 MG Comprimidos Recubiertos con PeliculaSpain · 46.729 mgAuthorised
- Vizimpro 15 mg filmomhulde tablettenNetherlandsAuthorised
- Vizimpro 30 mg filmomhulde tabletten